{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T03:55:31Z","timestamp":1775015731402,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T00:00:00Z","timestamp":1635552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine: X"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jvacx.2021.100127","type":"journal-article","created":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T16:56:25Z","timestamp":1636736185000},"page":"100127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Examination of scenarios introducing rubella vaccine in the Democratic Republic of the Congo"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2281-1798","authenticated-orcid":false,"given":"Alvan","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3383-2730","authenticated-orcid":false,"given":"Kurt","family":"Frey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume Ngoie","family":"Mwamba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9148-8448","authenticated-orcid":false,"given":"Kevin A.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1770-6304","authenticated-orcid":false,"given":"Nicole A.","family":"Hoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0662-9067","authenticated-orcid":false,"given":"Anne W.","family":"Rimoin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvacx.2021.100127_b0005","first-page":"301","article-title":"Rubella vaccines: WHO position paper","volume":"86","author":"World Health Organization","year":"2011","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.jvacx.2021.100127_b0010","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.15585\/mmwr.mm6645a4","article-title":"Progress in Rubella and Congenital Rubella Syndrome Control and Elimination \u2014 Worldwide, 2000\u20132016","volume":"66","author":"Grant","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jvacx.2021.100127_b0015","first-page":"69","article-title":"Control of rubella and congenital rubella syndrome (CRS) in developing countries, Part 2: Vaccination against rubella","volume":"75","author":"Robertson","year":"1997","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.jvacx.2021.100127_b0020","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.2105\/AJPH.90.10.1555","article-title":"Unseen blindness, unheard deafness, and unrecorded death and disability: congenital rubella in Kumasi, Ghana","volume":"90","author":"Lawn","year":"2000","journal-title":"Am J Public Health"},{"issue":"3","key":"10.1016\/j.jvacx.2021.100127_b0025","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.siny.2007.01.017","article-title":"Rubella","volume":"12","author":"Best","year":"2007","journal-title":"Semin Fetal Neonatal Med"},{"issue":"13","key":"10.1016\/j.jvacx.2021.100127_b0030","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/pd.4467","article-title":"Rubella and pregnancy: diagnosis, management and outcomes","volume":"34","author":"Bouthry","year":"2014","journal-title":"Prenat Diagn"},{"issue":"14","key":"10.1016\/j.jvacx.2021.100127_b0035","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1016\/j.vaccine.2005.12.015","article-title":"Waning antibodies in measles and rubella vaccinees\u2014a longitudinal study","volume":"24","author":"Kremer","year":"2006","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.jvacx.2021.100127_b0040","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s15010-007-6337-z","article-title":"Safety and Immunogenicity of Early Vaccination with Two Doses of Tetravalent Measles-Mumps-Rubella-Varicella (MMRV) Vaccine in Healthy Children from 9 Months of Age","volume":"35","author":"Goh","year":"2007","journal-title":"Infection"},{"issue":"4","key":"10.1016\/j.jvacx.2021.100127_b0045","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00006454-199004000-00008","article-title":"Measles, mumps and rubella immunization at nine months in a developing country","volume":"9","author":"Schoub","year":"1990","journal-title":"Pediatr Infect Dis J"},{"issue":"51","key":"10.1016\/j.jvacx.2021.100127_b0050","doi-asserted-by":"crossref","first-page":"6502","DOI":"10.1016\/j.vaccine.2016.10.059","article-title":"Estimating the burden of rubella virus infection and congenital rubella syndrome through a rubella immunity assessment among pregnant women in the Democratic Republic of the Congo: Potential impact on vaccination policy","volume":"34","author":"Alleman","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2021.100127_b0055","doi-asserted-by":"crossref","unstructured":"Alfonso VH, Doshi RH, Mukadi P, Higgins SG, Hoff NA, Bwaka A, et al. Prevalence of Rubella Antibodies among Children in the Democratic Republic of the Congo. Pediatr Infect Dis J 2018;37:28\u201334. http:\/\/doi.org\/10.1097\/INF.0000000000001703.","DOI":"10.1097\/INF.0000000000001703"},{"key":"10.1016\/j.jvacx.2021.100127_b0060","doi-asserted-by":"crossref","unstructured":"Zhou F, Reef S, Massoudi M, Yusuf HR, Bardenheier B, Zimmerman L, et al. An Economic Analysis of the Current Universal 2-dose measles-mumps-rubella Vaccination Program in the United States. J Infect Dis 2004;189:S131\u201345. http:\/\/doi.org\/10.1086\/378987.","DOI":"10.1086\/378987"},{"key":"10.1016\/j.jvacx.2021.100127_b0065","first-page":"74","article-title":"Cost-benefit analysis of routine mumps and rubella vaccination for Israeli infants","volume":"26","author":"Berger","year":"1990","journal-title":"Isr J Med Sci"},{"issue":"3","key":"10.1016\/j.jvacx.2021.100127_b0070","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0033-3506(84)80043-8","article-title":"Cost-benefit analysis of alternative programs of vaccination against rubella in Israel","volume":"98","author":"Golden","year":"1984","journal-title":"Public Health"},{"issue":"12","key":"10.1016\/j.jvacx.2021.100127_b0075","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.11150\/kansenshogakuzasshi1970.74.1012","article-title":"Kataoka N","volume":"74","author":"Terada","year":"2000","journal-title":"Kansenshogaku Zasshi"},{"issue":"Suppl 1","key":"10.1016\/j.jvacx.2021.100127_b0080","doi-asserted-by":"crossref","first-page":"S200","DOI":"10.1093\/clinids\/7.Supplement_1.S200","article-title":"Cost-effectiveness of different strategies for prevention of congenital rubella infection: a practical example from Iceland","volume":"7","author":"Gudnad\u00f3ttir","year":"1985","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.jvacx.2021.100127_b0085","first-page":"69","article-title":"Economic evaluation of different vaccination programmes to prevent congenital rubella","volume":"5","author":"Stray-Pedersen","year":"1982","journal-title":"NIPH Ann"},{"issue":"2","key":"10.1016\/j.jvacx.2021.100127_b0090","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1017\/S002217240002893X","article-title":"Vaccination against rubella and measles: quantitative investigations of different policies","volume":"90","author":"Anderson","year":"1983","journal-title":"J Hyg (Lond)"},{"issue":"1","key":"10.1016\/j.jvacx.2021.100127_b0095","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/ije\/9.1.13","article-title":"Strategy for rubella vaccination","volume":"9","author":"Knox","year":"1980","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jvacx.2021.100127_b0100","unstructured":"World Health Organisation (WHO). Summary of the WHO position on Rubella Vaccine - July 2020. 2020."},{"key":"10.1016\/j.jvacx.2021.100127_b0105","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1136\/bmj.319.7223.1462","article-title":"Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review","volume":"319","author":"Panagiotopoulos","year":"1999","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.jvacx.2021.100127_b0110","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.tpb.2011.12.001","article-title":"Structured models of infectious disease: Inference with discrete data","volume":"82","author":"Metcalf","year":"2012","journal-title":"Theor Popul Biol"},{"issue":"78","key":"10.1016\/j.jvacx.2021.100127_b0115","doi-asserted-by":"crossref","first-page":"20120756","DOI":"10.1098\/rsif.2012.0756","article-title":"Implications of spatially heterogeneous vaccination coverage for the risk of congenital rubella syndrome in South Africa","volume":"10","author":"Metcalf","year":"2013","journal-title":"J R Soc Interface"},{"key":"10.1016\/j.jvacx.2021.100127_b0120","unstructured":"World Health Organisation (WHO). WHO-UNICEF Vaccine Coverage Estimates 2020. https:\/\/immunizationdata.who.int\/ (accessed July 20, 2021)."},{"issue":"1","key":"10.1016\/j.jvacx.2021.100127_b0125","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1473-3099(11)70362-0","article-title":"GAVI Alliance to roll out rubella vaccine","volume":"12","author":"Burki","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"45","key":"10.1016\/j.jvacx.2021.100127_b0130","doi-asserted-by":"crossref","first-page":"6187","DOI":"10.1016\/j.vaccine.2017.09.038","article-title":"Assessing the cost-effectiveness of different measles vaccination strategies for children in the Democratic Republic of Congo","volume":"35","author":"Doshi","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2021.100127_b0135","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41586-020-03043-4","article-title":"Mapping routine measles vaccination in low- and middle-income countries","volume":"589","author":"Sbarra","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jvacx.2021.100127_b0140","doi-asserted-by":"crossref","unstructured":"Keeling MJ, Rohani P. Modeling Infectious Diseases in Humans and Animals. Princeton University Press; 2008. doi:10.2307\/j.ctvcm4gk0.","DOI":"10.1515\/9781400841035"},{"key":"10.1016\/j.jvacx.2021.100127_b0145","doi-asserted-by":"crossref","unstructured":"MASSAD E. An Introduction to Infectious Diseases Modelling. By E. Vynnycky and R. White (400 pp.; \u00a329.95; ISBN 978-0-19-856576-5 pb). Oxford: Oxford University Press, 2010. Epidemiol Infect 2011;139:1126. doi:DOI: 10.1017\/S0950268811000422.","DOI":"10.1017\/S0950268811000422"},{"key":"10.1016\/j.jvacx.2021.100127_b0150","doi-asserted-by":"crossref","unstructured":"Kretzschmar M, Wallinga J. Mathematical Models in Infectious Disease Epidemiology. Mod Infect Dis Epidemiol Concepts, Methods, Math Model Public Heal 2009:209\u201321. doi:10.1007\/978-0-387-93835-6_12.","DOI":"10.1007\/978-0-387-93835-6_12"},{"key":"10.1016\/j.jvacx.2021.100127_b0155","unstructured":"Demographic and Health Survey. Democratic Republic of the Congo Demographic and Health Survey 2013-2014 Supplemental Vaccine-preventable Diseases Report 2015."},{"key":"10.1016\/j.jvacx.2021.100127_b0160","unstructured":"The DHS Program - Survey Process n.d."},{"issue":"5","key":"10.1016\/j.jvacx.2021.100127_b0165","doi-asserted-by":"crossref","first-page":"e1001391","DOI":"10.1371\/journal.pmed.1001391","article-title":"Measuring Coverage in MNCH: Tracking Progress in Health for Women and Children Using DHS and MICS Household Surveys","volume":"10","author":"Hancioglu","year":"2013","journal-title":"PLOS Med"},{"key":"10.1016\/j.jvacx.2021.100127_b0170","series-title":"Sampling and Household Listing Manual","author":"ICF International","year":"2012"},{"issue":"1","key":"10.1016\/j.jvacx.2021.100127_b0175","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jviromet.2006.06.018","article-title":"Comparison of available methods to elute serum from dried blood spot samples for measles serology","volume":"137","author":"Mercader","year":"2006","journal-title":"J Virol Methods"},{"issue":"4","key":"10.1016\/j.jvacx.2021.100127_b0180","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00112-19","article-title":"Field Test and Validation of the Multiplier Measles, Mumps, Rubella, and Varicella-Zoster Multiplexed Assay System in the Democratic Republic of the Congo by Using Dried Blood Spots","volume":"4","author":"Higgins","year":"2019","journal-title":"MSphere"},{"key":"10.1016\/j.jvacx.2021.100127_b0185","series-title":"Module 11: Rubella","author":"World Health Organization","year":"2008"},{"issue":"2","key":"10.1016\/j.jvacx.2021.100127_b0190","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/ajcp\/106.2.170","article-title":"Rubella immunity. Defining the level of protective antibody","volume":"106","author":"Skendzel","year":"1996","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jvacx.2021.100127_b0195","doi-asserted-by":"crossref","unstructured":"Bershteyn A, Gerardin J, Bridenbecker D, Lorton CW, Bloedow J, Baker RS, et al. Implementation and applications of EMOD, an individual-based multi-disease modeling platform. Pathog Dis 2018;76. http:\/\/doi.org\/10.1093\/femspd\/fty059.","DOI":"10.1093\/femspd\/fty059"},{"key":"10.1016\/j.jvacx.2021.100127_b0200","doi-asserted-by":"crossref","unstructured":"Fine P, Eames K, Heymann DL. \u201cHerd Immunity\u201d: A Rough Guide. Clin Infect Dis 2011;52:911\u20136. http:\/\/doi.org\/10.1093\/cid\/cir007.","DOI":"10.1093\/cid\/cir007"},{"key":"10.1016\/j.jvacx.2021.100127_b0205","doi-asserted-by":"crossref","unstructured":"Winter AK, Martinez ME, Cutts FT, Moss WJ, Ferrari MJ, McKee A, et al. Benefits and Challenges in Using Seroprevalence Data to Inform Models for Measles and Rubella Elimination. J Infect Dis 2018;218:355\u201364. http:\/\/doi.org\/10.1093\/infdis\/jiy137.","DOI":"10.1093\/infdis\/jiy137"},{"issue":"12","key":"10.1016\/j.jvacx.2021.100127_b0210","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1017\/S0950268812000131","article-title":"Impact of birth rate, seasonality and transmission rate on minimum levels of coverage needed for rubella vaccination","volume":"140","author":"METCALF","year":"2012","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.jvacx.2021.100127_b0215","doi-asserted-by":"crossref","unstructured":"Graham M, Winter AK, Ferrari M, Grenfell B, Moss WJ, Azman AS, et al. Measles and the canonical path to elimination. Science (80-) 2019;364:584 LP \u2013 587. http:\/\/doi.org\/10.1126\/science.aau6299.","DOI":"10.1126\/science.aau6299"},{"issue":"9838","key":"10.1016\/j.jvacx.2021.100127_b0220","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(12)61215-X","article-title":"Rubella vaccination: must not be business as usual","volume":"380","author":"Cutts","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jvacx.2021.100127_b0225","article-title":"University of Southampton; Department of Geography and Geosciences, University of Louisville; Departement de Geographie, Universite de Namur; Center for International Earth Science Information Network (CIESIN CU","author":"School of Geography and Environmental Science","year":"2018","journal-title":"WorldPop"}],"updated-by":[{"DOI":"10.1016\/j.jvacx.2022.100215","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000}}],"container-title":["Vaccine: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136221000449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136221000449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T23:11:03Z","timestamp":1639869063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590136221000449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":45,"alternative-id":["S2590136221000449"],"URL":"https:\/\/doi.org\/10.1016\/j.jvacx.2021.100127","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.jvacx.2022.100215","asserted-by":"object"}]},"ISSN":["2590-1362"],"issn-type":[{"value":"2590-1362","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Examination of scenarios introducing rubella vaccine in the Democratic Republic of the Congo","name":"articletitle","label":"Article Title"},{"value":"Vaccine: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvacx.2021.100127","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100127"}}